Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Cue Biopharma, Inc. (CUE)
|
Add to portfolio |
|
|
|
| Price: |
$11.81
| | Metrics |
| OS: |
45.0
|
M
| |
|
|
| Market cap: |
$531
|
M
| |
|
|
|
Net cash:
|
$53.9
|
M
| |
$1.20
|
per share
|
|
EV:
|
$477
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 1.2 | 14.9 | 3.2 | 3.5 | 1.1 | 0.0 | 0.0 | 0.0 |
| Revenue growth | -91.7% | 373.7% | -8.8% | 202.7% | | | | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 1.2 | 14.9 | 3.2 | 3.5 | 1.1 | 0.0 | 0.0 | 0.0 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | | | |
| Selling, general and administrative | 54.5 | 58.7 | 48.2 | | | | | |
| Research and development | | | | 27.5 | 28.5 | 18.9 | 5.7 | 1.5 |
| General and administrative | | | | 12.7 | 11.3 | 4.3 | 2.0 | 0.4 |
| EBITA | -52.8 | -43.6 | -45.1 | -36.8 | -38.7 | -23.2 | -7.7 | -1.9 |
| EBITA margin | -4239.9% | -291.9% | -1431.1% | -1062.9% | -3386.7% | | | |
| Amortization of intangibles | | | | 0.0 | | | | |
| EBIT | -52.8 | -43.6 | -45.1 | -36.8 | -38.7 | -23.2 | -7.7 | -1.9 |
| EBIT margin | -4239.9% | -291.9% | -1431.1% | -1063.2% | -3386.7% | | | |
| Pre-tax income | -53.0 | -43.7 | -44.6 | -36.3 | -38.2 | -23.2 | -7.7 | -1.9 |
| Income taxes | 0.0 | 0.5 | 0.2 | 0.4 | 0.8 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | | | | | 0.0% | 0.0% | 0.0% |
| Net income | -53.0 | -44.2 | -44.8 | -36.7 | -39.0 | -23.2 | -7.7 | -1.9 |
| Net margin | -4257.1% | -295.6% | -1419.8% | -1061.2% | -3411.5% | | | |
| |
| Diluted EPS | ($1.49) | ($1.41) | ($1.56) | ($1.66) | ($1.94) | ($2.16) | ($1.03) | ($0.34) |
| Shares outstanding (diluted) | 35.6 | 31.3 | 28.7 | 22.0 | 20.1 | 10.7 | 7.4 | 5.7 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|